NECLIFENSENectar Lifesciences Limited· PharmaceuticalsHighNeutral
Announced Wed, 3 Dec · 19:05 IST

Nectar Lifesciences Limited has informed the Exchange regarding Appointment of Mr. Sushil Kapoor as an additional Director as well Wholetime Director designated as Director (Finance) of the company w.e.f. December 04, 2025.

Management Changes View source PDF

NECLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Nectar Lifesciences Limited has appointed Mr. Sushil Kapoor as an additional Director on its board, with the designation of Wholetime Director (Finance), effective December 04, 2025. He will serve in a whole-time executive capacity handling the finance function of the company. As an additional director, he will hold office until the next general meeting and is also being appointed as a Wholetime Director subject to shareholder approval. This is a key managerial personnel addition in the finance leadership role.

Likely market impact

This appointment brings a dedicated finance head to the board, which may strengthen financial oversight and reporting at Nectar Lifesciences. Shareholders typically view such KMP additions as a governance positive, though the stock price impact is expected to be neutral to mildly positive.